Dendreon Corporation (NASDAQ: DNDN) announced today the presentation of data from clinical studies featuring PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for metastatic castrate-resistant prostate cancer (mCRPC), at the 2013 European Cancer Congress in Amsterdam, September 27-October 1, 2013. Preliminary Phase II data surrounding DN24-02, an investigational autologous cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer, will also be presented.
Help employers find you! Check out all the jobs and post your resume.
